The estimated Net Worth of Terrence F Blaschke is at least $44 Tisíc dollars as of 27 September 2017. Terrence Blaschke owns over 25,000 units of Durect Corp stock worth over $43,960 and over the last 18 years Terrence sold DRRX stock worth over $0.
Terrence has made over 2 trades of the Durect Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently Terrence exercised 25,000 units of DRRX stock worth $20,500 on 27 September 2017.
The largest trade Terrence's ever made was exercising 25,000 units of Durect Corp stock on 27 September 2017 worth over $20,500. On average, Terrence trades about 1,120 units every 22 days since 2006. As of 27 September 2017 Terrence still owns at least 28,000 units of Durect Corp stock.
You can see the complete history of Terrence Blaschke stock trades at the bottom of the page.
Terrence's mailing address filed with the SEC is C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO, CA, 95014.
Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management... a Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Durect Corp executives and other stock owners filed with the SEC include: